Skip to main content
SpringerLink
Log in

Single-tablet RPV/FTC/TDF improves SPIRIT

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. supported by Gilead Sciences

Reference

  • Brunetta J, et al. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. The Patient - Patient-Centered Outcomes Research : 26 Mar 2015. Available from: URL: http://doi.org/10.1007/s40271-015-0123-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Single-tablet RPV/FTC/TDF improves SPIRIT. PharmacoEcon Outcomes News 725, 28 (2015). https://doi.org/10.1007/s40274-015-2042-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2042-9

Search

Navigation